



Form PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		<b>Complete If Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/643,829		
		Filing Date	08/19/03		
		First Named Inventor	LIU, et al.		
		Group Art Unit	1643		
		Examiner Name	AM Harris, Ph.D.		
Sheet	1	of	1	Attorney Docket Number	P05779US1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
amh	1	ROBERT C. BAST, et al., Reactivity of a Monoclonal Antibody with Human Ovarian Carcinoma, J. Clin. Invest., Volume 68, November 1981, 1331-1337	
J	2	THOMAS L. KLUG, et al., Monoclonal Antibody Immunoradiometric Assay for an Antigenic Determinant (CA 125) Associated with Human Epithelial Ovarian Carcinomas, Cancer Research 44, 1048-1053, March 1984	
J	3	GIJSBERT G. BON, et al., Serum tumor marker immunoassays in gynecologic oncology: Establishment of reference values, Am J Obstet Gynecol 1996; 174:107-14.	
amh	4	K. NUSTAD, et al., CA 125 – epitopes and molecular size, The International Journal of Biological Markers, Vol. 13 No.4, pp. 196-199, 1998	
amh	5	IAN G. CAMPBELL, et al., A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1, Human Molecular Genetics, 1994, Vol. 3, No. 4, 589-594	
amh	6	CAROLINE WHITEHOUSE, et al., NBR1 interacts with fasciculation and elongation protein zeta-1 (FEZ1) and calcium and integrin binding protein (CIB) and shows developmentally restricted expression in the neural tube, Eur. J. Biochem. 269, 538-545 (2002)	
J	7	BEATRICE W. T. YIN and KENNETH O. LLOYD, Molecular Cloning of the CA125 Ovarian Cancer Antigen, The Journal of Biological Chemistry, Vol. 276, No. 29, Issue of July 20, pp. 27371-27375, 2001	
J	8	TIMOTHY J. O'BRIEN et al., The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences, Tumor Biol 2001; 22:348-366	
amh	9	WILLIAM H. KUTTEH, et al., Immunologic Characterization of Tumor Markers in Human Ovarian Cancer Cell Lines, J Soc Gynecol Invest 1996; 3:216-22	
amh	10	CAROLINE WHITEHOUSE and ELLEN SOLOMON, Current Status of the Molecular Characterization of the Ovarian Cancer Antigen CA125 and Implications for Its Use in Clinical Screening, Gynecologic Oncology 88, S152-S157 (2003)	
J	11	STOIL DIMITROV et al., Expression profiles and intergenic structure of head-to-head oriented <i>Brca1</i> and <i>Nbr1</i> genes, Gene 262 (2001) 89-98	
J	12	KATSUYUKI HAMADA et al., Identification of the Human IAI.3B Promoter Element and Its Use in the Construction of a Replication-selective Adenovirus for Ovarian Cancer Therapy, Cancer Research 63, 2506-2512, May 15, 2003	

Examiner Signature	<i>AM Harris</i>	Date Considered	08/31/2003
--------------------	------------------	-----------------	------------

\* EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.